Scarica l'app Stockscreener
9.88
1.69%
-0.17
Pre-mercato:
9.79
-0.09
-0.91%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché RNAZ Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$10.05
Aprire:
$9.94
Volume 24 ore:
15,230
Relative Volume:
0.07
Capitalizzazione di mercato:
$9.06M
Reddito:
-
Utile/perdita netta:
$-14.93M
Rapporto P/E:
-0.0371
EPS:
-266.137
Flusso di cassa netto:
$-15.87M
1 W Prestazione:
-0.90%
1M Prestazione:
+24.28%
6M Prestazione:
-14.12%
1 anno Prestazione:
-96.73%
Intervallo 1D:
$9.3001
$10.05
Intervallo di 1 settimana:
$7.9914
$11.08
Portata 52W:
$6.0829
$316.28
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Nome
Transcode Therapeutics Inc
Settore
Industria
Telefono
857-301-6857
Indirizzo
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
9.88 | 9.22M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Transcode Therapeutics Inc Borsa (RNAZ) Ultime notizie
What’s the beta of TransCode Therapeutics Inc. stockJuly 2025 Sentiment & Daily Stock Trend Watchlist - mfd.ru
Big Money Moves: Whats the beta of TransCode Therapeutics Inc stockWeekly Stock Recap & Trade Opportunity Analysis - baoquankhu1.vn
TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial - TechStock²
Therapeutics, Inc. (RNAZ) Stock: Jumps as Company Expands RNA Cancer Program into Colorectal Indication - parameter.io
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
TransCode Therapeutics Unveils Promising Glioblastoma Data with TTX-MC138 - timothysykes.com
TransCode Therapeutics’ TTX-MC138 Excites Market with Promising Glioblastoma Data - StocksToTrade
TransCode Therapeutics: Promising Data Boosts Future Outlook - timothysykes.com
TransCode Therapeutics Advances Phase 2a Colorectal Cancer Trial - TipRanks
TransCode Therapeutics Announces IND Amendment for Phase 2a Trial - TradingView
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial With TTX-MC138 - 富途牛牛
Aug Sentiment: Does TransCode Therapeutics Inc have pricing powerEarnings Performance Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Aug Gainers: Why is TransCode Therapeutics Inc stock going downCPI Data & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Risk Analysis: Whats the beta of TransCode Therapeutics Inc stockJuly 2025 Spike Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Aug Intraday: What’s the beta of TransCode Therapeutics Inc. stock2025 Trading Recap & Free Weekly Watchlist of Top Performers - mfd.ru
What are analysts’ price targets for TransCode Therapeutics Inc.July 2025 Patterns & Entry Point Strategy Guides - mfd.ru
Earnings Recap: Is TransCode Therapeutics Inc a good stock for dollar cost averagingPortfolio Performance Summary & Weekly Breakout Watchlists - baoquankhu1.vn
Market Recap: Is TransCode Therapeutics Inc a good stock for dollar cost averagingJuly 2025 PostEarnings & Stepwise Trade Signal Guides - baoquankhu1.vn
Short Squeeze: Should I hold or sell TransCode Therapeutics Inc nowJuly 2025 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
Market Catalysts: Is TransCode Therapeutics Inc a speculative investmentQuarterly Portfolio Report & Fast Gain Swing Alerts - baoquankhu1.vn
Entry Recap: How does OLPX compare to its peersWeekly Profit Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
Is TransCode Therapeutics Inc. stock in correction or buying zone2025 Volume Leaders & High Yield Equity Trading Tips - bollywoodhelpline.com
Options Flow: Does TransCode Therapeutics Inc have pricing powerJuly 2025 Earnings & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Fundamentals Check: Is TransCode Therapeutics Inc attractive for institutional investors2025 Trade Ideas & AI Based Buy and Sell Signals - baoquankhu1.vn
Bull Bear: What are analysts price targets for TransCode Therapeutics IncJuly 2025 Pullbacks & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Market Recap: What are analysts price targets for TransCode Therapeutics IncJuly 2025 Technicals & Reliable Price Breakout Alerts - baoquankhu1.vn
Will TransCode Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Gainers & AI Powered Market Entry Strategies - Улправда
MSN Money - MSN
Is TransCode Therapeutics Inc. stock attractive for income investorsBreathability and Upper Notes & HOKA model picks for your routine - ulpravda.ru
Will TransCode Therapeutics Inc. stock split again soonJuly 2025 Closing Moves & Weekly High Return Stock Opportunities - Улправда
Why retail investors pile into TransCode Therapeutics Inc. stockWeekly Trade Review & Reliable Entry Point Alerts - Улправда
TransCode Therapeutics, Inc.Common Stock (NQ: RNAZ - FinancialContent
Can TransCode Therapeutics Inc. stock double in next 5 years2025 Volatility Report & Risk Managed Trade Strategies - Улправда
TransCode’s glioblastoma therapy shows promise in preclinical study By Investing.com - Investing.com Nigeria
(RNAZ) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
How TransCode Therapeutics Inc. stock benefits from tech adoption2026 world cup usa national team quarterfinals midfield engines counter attacking knockout prediction tactical review - ulpravda.ru
TransCode Therapeutics Publishes Preclinical Data Supporting TTX-MC138 for Glioblastoma Treatment - citybuzz -
Transcode Therapeutics Ttx-Mc138 phase 2a clinical trial expected in first half of 2026 - marketscreener.com
Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026 - TradingView — Track All Markets
TransCode Therapeutics reports promising preclinical glioblastoma results - TipRanks
TransCode Therapeutics stock soars after promising glioblastoma study By Investing.com - Investing.com Canada
TransCode Therapeutics Publishes Preclinical Data on TTX-MC138 for Glioblastoma - TradingView — Track All Markets
TransCode’s glioblastoma therapy shows promise in preclinical study - Investing.com
Experimental RNA therapy extends survival in brain cancer animal tests - Stock Titan
TransCode reports positive phase 1 trial progress for cancer therapy - MSN
Precision Trading with Transcode Therapeutics Inc. (RNAZ) Risk Zones - Stock Traders Daily
TransCode Therapeutics appoints Jack E. Stover to board of directors By Investing.com - Investing.com Nigeria
TransCode Therapeutics Appoints Industry Veteran Jack E. Stover to Board of Directors - citybuzz -
TransCode Therapeutics Strengthens Board with Veteran Financial Expert - TipRanks
Transcode Therapeutics Appoints Jack Stover to Board of Directors - TradingView — Track All Markets
TransCode Therapeutics appoints Jack E. Stover to board of directors - Investing.com India
Transcode Therapeutics Inc Azioni (RNAZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):